Overview

Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.
Phase:
PHASE1
Details
Lead Sponsor:
Stanford University
Collaborator:
Incyte Corporation